Geropharm to build what is expected to be Russia's largest pharma plant

23 March 2016

Geropharm, one of Russia’s largest drugmakers, has signed an agreement with VTB, Russia’s leading state-owned bank, on the provision of a loan for the building of a new pharmaceutical plant in Russia, which is expected to be one of the largest in the country.

The new plant will be built in the Pushkin district of St Petersburg, while the overall volume of investments in the project is expected to reach 4 billion roubles ($58.8 million).

The new plant should be officially commissioned on December 28, 2017. In addition to drug production itself, the new facility will focus on the manufacture of pharmaceutical substances which, to date, have been fully imported into Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK